Cart
sales@molnova.com
PDGFR Tyrosine Kinase Inhibitor III
CAS No. 205254-94-0
PDGFR Tyrosine Kinase Inhibitor III( —— )
Catalog No. M35325 CAS No. 205254-94-0
PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III) is a multikinase inhibitor that inhibits PDGFR, EGFR, FGFR, PKA, and PKC and can be used for research on amyotrophic lateral sclerosis .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 46 | Get Quote |
|
| 5MG | 69 | Get Quote |
|
| 10MG | 112 | Get Quote |
|
| 25MG | 251 | Get Quote |
|
| 50MG | 363 | Get Quote |
|
| 100MG | 516 | Get Quote |
|
| 500MG | 1035 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePDGFR Tyrosine Kinase Inhibitor III
-
NoteResearch use only, not for human use.
-
Brief DescriptionPDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III) is a multikinase inhibitor that inhibits PDGFR, EGFR, FGFR, PKA, and PKC and can be used for research on amyotrophic lateral sclerosis .
-
DescriptionPDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDGFR
-
RecptorPDGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number205254-94-0
-
Formula Weight485.53
-
Molecular FormulaC27H27N5O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (205.96 mM; Ultrasonic (<60°C)
-
SMILESO(C)C1=CC=2C(=NC=NC2C=C1OC)N3CCN(C(NC4=CC=C(OC5=CC=CC=C5)C=C4)=O)CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Young-Min Lee. Compositions and methods for zika virus characterization and vaccine development. WO2019204654A1.
molnova catalog
related products
-
Toceranib
Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.
-
CT52923
CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor.
-
Regorafénib N-oxyde ...
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1.
